299 related articles for article (PubMed ID: 7873647)
1. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
Schott ME; Frazier KA; Pollock DK; Verbanac KM
Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
[TBL] [Abstract][Full Text] [Related]
3. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
4. A cross-linked monoclonal antibody fragment for improved tumor targeting.
Stalteri MA; Mather SJ
Bioconjug Chem; 1995; 6(2):179-86. PubMed ID: 7599261
[TBL] [Abstract][Full Text] [Related]
5. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
6. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.
Quadri SM; Lai J; Mohammadpour H; Vriesendorp HM; Williams JR
J Nucl Med; 1993 Dec; 34(12):2152-9. PubMed ID: 8254403
[TBL] [Abstract][Full Text] [Related]
7. Dextran modification of a Fab'--beta-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents.
Mikolajczyk SD; Meyer DL; Fagnani R; Hagan MS; Law KL; Starling JJ
Bioconjug Chem; 1996; 7(1):150-8. PubMed ID: 8742004
[TBL] [Abstract][Full Text] [Related]
8. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
[TBL] [Abstract][Full Text] [Related]
11. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
[TBL] [Abstract][Full Text] [Related]
12. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells.
Khawli LA; Biela BH; Hu P; Epstein AL
Hybrid Hybridomics; 2002 Feb; 21(1):11-8. PubMed ID: 11991812
[TBL] [Abstract][Full Text] [Related]
13. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
Peräalä-Heape M; Vihko P; Vihko R
Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
[TBL] [Abstract][Full Text] [Related]
14. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model.
Quadri SM; Siddiqui A; Klein JL; Vriesendorp HM
Nucl Med Biol; 1995 May; 22(4):413-23. PubMed ID: 7550017
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
[TBL] [Abstract][Full Text] [Related]
19. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
Leung SO; Qu Z; Hansen HJ; Shih LB; Wang J; Losman MJ; Goldenberg DM; Sharkey RM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
